Related Experiment Video
Updated: Aug 14, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions
Melissa D Johnson1, Michael Kleinberg, Larry Danziger
1Division of Infectious Diseases, Department of Medicine, Duke University Medical Centre, Box 3306, Durham, NC 27710, USA. johns200@mc.duke.edu
Abstract:
The frequency and severity of invasive fungal infections have been increasingly recognised and new antifungal therapies have expanded the therapeutic armamentarium available to manage such infections. Antifungal agents comprise a significant portion of antibiotic expenditures at major medical centres, prompting adoption of cost-containment measures and treatment guidelines. This paper reviews available data regarding the costs associated with managing fungal infections, including pharmacoeconomic analyses that have been performed in the setting of documented fungal infections, as well as prophylactic and empiric use of antifungal agents. The challenges of performing such studies are discussed, as well as the limitations of published investigations. Finally, recommendations are made regarding the design and implementation of future pharmacoeconomic analyses that can help establish the true costs of managing invasive fungal infections in at-risk patient populations.
Related Concept Videos
Antifungal Agents
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Fungal Phylum Microsporidia
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacogenomics: Identification of New Drug Targets
